CX-5461

Phase 1Small molecule

SSenhwa Biosciences, Inc.

CX-5461 is one of 2 small molecule programs targeting Homologous Recombination Deficiency. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Homologous Recombination DeficiencyRecruiting

Homologous Recombination DeficiencyPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Homologous Recombination Deficiency

#DrugCompanyPhaseTrials

Zejula

GGlaxo Dba Glaxosmithkline

Phase 2

2 2

CX-5461

SSenhwa Biosciences, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Homologous Recombination Deficiency

NCT04890613

Clinical

Trials by Indication[1]

Homologous Recombination Deficiency1 trial

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Recruiting·SSenhwa Biosciences, Inc.·Phase 1·NCT04890613·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CX-5461. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CX-5461 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CX-5461. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Senhwa Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSenhwa Biosciences, Inc.

CX-5461

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Homologous Recombination Deficiency1 trial

References

Drug Info

Quick Facts

Related News